Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1

Status

Terminated 5Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Sarcoma 2Other hematologic neoplasm 2Thoracic 1Myeloid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Dermatologic 1Breast 1

Conditions

Sarcoma 2Recurrence 2Leukemia, Myeloid, Acute 2Uterine Cervical Neoplasms 1Testicular Germ Cell Tumor 1Stomach Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Myelodysplastic Syndromes 1Melanoma 1Liposarcoma 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Biliary Tract Neoplasms 1Adrenocortical Carcinoma 1Adenocarcinoma of Lung 1

Interventions

Cyclophosphamide 390Carboplatin 344Gemcitabine 332pembrolizumab 329Cisplatin 328Paclitaxel 297Radiotherapy 296Docetaxel 286Bevacizumab 253Rituximab 234Capecitabine 223Nivolumab 220Dexamethasone 206Fluorouracil 190fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 133Cetuximab 129Bortezomib 129fludarabine phosphate 128Lenalidomide 126Erlotinib Hydrochloride 120Filgrastim 119Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Terminated × milademetan × Clear all
NCT04979442 2025-01-14

MANTRA

Rain Oncology Inc

Phase 3 Terminated
175 enrolled 16 charts
Sarcoma

Liposarcoma, Sarcoma

NCT05012397 2024-10-17

Milademetan in Advanced/Metastatic Solid Tumors

Rain Oncology Inc

Phase 2 Terminated
40 enrolled 13 charts
DermatologicEndocrineGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Testicular Germ Cell Tumor, Adenocarcinoma of Lung, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Adrenocortical Carcinoma, Cholangiocarcinoma

NCT05932667 2023-12-21

DEMETER

Institut Curie

Phase 2 Terminated
1 enrolled
Breast

Breast Neoplasms

NCT03552029 2022-05-20

Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)

Daiichi Sankyo

Phase 1 Terminated
10 enrolled 10 charts
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT02319369 2021-10-11

Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Daiichi Sankyo

Phase 1 Terminated
74 enrolled 30 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡